Pfizer and BioNTech release preliminary phase I data for BNT162b COVID-19 vaccine

At the 30mcg dose, 7 days after the second dose, the BNT162b vaccine has demonstrated strong immunogenicity in younger and older adults and was well tolerated. These data supported its advancement into a 30,000-patient Phase 2/3 global study that started in July 2020.


Biospace Inc.